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ABSTRACT 
Intradialytic parental nutrition is a form of supplemental nutrition used to treat 
hemodialysis patients with malnutrition. Once the diagnosis of malnutrition is made in 
such patients encouragement of oral intake is the first-line treatment. If this fails, then 
enteral or parental nutrition may be needed.   This review examines the literature on the 
use of intradialytic parental nutrition and summarizes the current recommendations. 
There is considerable controversy over indications and benefits of intradialytic parental 
nutrition and well-controlled, long-term studies are needed to help tease out these issues. 
In the interim, clinical judgment should be used when considering intradialytic 
parental nutrition for individual patients.  
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BACKGROUND 
The presence of protein energy malnutrition (PEM) can be quite common1-3 among the 
hundreds of thousands of US hemodialysis patients and independently predicts higher 
hospitalization rates, lower quality of life, and death.4 Causes of PEM in hemodialysis 
patients include reduced food intake from uremia, concurrent illnesses, alterations in the 
balance between hunger and satiety hormones, dietary restrictions, financial limitations, 
depression/anxiety, and nutrient and energy losses that occur during the hemodialysis 
session.3, 4,5 
 
Prevention of PEM requires a multidisciplinary effort involving the entire health care 
team. Essential steps to improving nutritional status include liberalizing any dietary 
restrictions, encouraging food intake, providing oral nutrition supplements and offering 
nutritional education. However, these interventions are not always effective in helping 
the patient achieve their nutrition goals. In such cases, intradialytic parenteral nutrition 
(IDPN), which involves an intravenous infusion of essential nutrients during 
hemodialysis treatments, may be helpful as a component of nutritional support. 
 
This discussion will focus on the use of IDPN for in-center maintenance hemodialysis 
patients, which comprise the great majority of dialysis patients in the US, and review 
technical aspects and administration, the appropriate selection of patients, risks and 
benefits, and evidence supporting its use. The use of IDPN in patients on home and 
peritoneal dialysis will not be covered in this report. 
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TECHNICAL ASPECTS  
There are two main types of IDPN. In compounded admixture-based IDPN all in one 
IDPN bags are mixed by a pharmacy based on individual patient needs. In commercial 
admixture based IDPN pre-mixed bags are provided for generic use. Of the two, 
commercial pre-mixed bags are far more popular since the process of compounding 
single bags based on specific patient needs is time consuming and adds cost.5 IDPN is 
administrated via intravenous infusion with an infusion pump during hemodialysis. 
Typically the most concentrated IDPN formula is used in order to reduce the risk of 
volume overload and fit the treatment within the usual time constraints of a standard 
hemodialysis session.  
 
A typical IDPN infusion provides 800 to 1200 kcal in the form of glucose, lipids, and 
amino acids (usually 30 to 60 g of the latter).6 However, some amino acids can be lost in 
the dialysate depending upon the hemodialysis filter used and if they have been reused.7 
Electrolyte-free admixtures (i.e. without sodium, potassium, and phosphorus) are also 
available.5 When taking into account amino acids and calories that can be lost with each 
hemodialysis session (i.e. 200 to 480 kcal energy, 10 to 12 g amino acids)8 not more than 
3000 kcal and 150 g of amino acids will be provided by IDPN with thrice weekly 
dialysis. Thus in a 70 kg patient, approximately 6 kcal/kg/day (target being 30-35 
kcal/kg/day)9,10 and 0.30 g/kg/day of amino acids (target being 1.2 g/kg/day of amino 
acids)9,10 are provided by IDPN, highlighting the fact that IDPN should only be used as 
supplemental nutrition in patients with a spontaneous oral nutrition intake of at least 25 
kcal/kg/day and 0.9 g/kg/day of amino acids.5,9,11,12  
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EVIDENCE SUPPORTING THE USE OF IDPN 
Several prospective randomized studies have examined the effects of IDPN on clinical 
endpoints. Benefits noted included improvements in anthropometric parameters and 
serum albumin and prealbumin levels.12-14 One human study that infused stable isotopes 
to assess muscle turnover during IDPN identified increases in regional and total body 
protein synthesis.15 However, in the largest randomized study of IDPN (n=186) the 
addition of IDPN to oral nutritional supplementation over 1 year did not improve 2-year 
mortality rates, hospitalization rates, or general well-being as compared to oral 
supplements alone.16 Additionally, all the randomized studies have been open-label in 
design, which increases the opportunity for bias. Moreover, while most studies used 
albumin as an inclusion criterion or surrogate outcome representing nutritional 
improvement, albumin is primarily an indicator of inflammation or illness thus making 
interpretation of these studies more challenging.17 Clearly longer term prospective 
clinical trials with appropriate control groups are needed to identify which type of patient 
is most likely to benefit from IDPN.12 
 
SELECTION OF PATIENTS FOR IDPN 
The process of selecting patients for IDPN first requires identifying patients who are 
malnourished. Table 1 includes a list of parameters from the National Kidney Foundation 
Disease Outcome Quality Initiative (NKF KDOQI) that can be used to identify 
malnutrition.11 As the table notes each of the parameters have limitations, sometimes 
serious ones, when applied to the hemodialysis population. Therefore identifying PEM in 
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hemodialysis patients requires a large dose of clinical judgment based on a careful history 
and physical examination. 
 
Once PEM is identified IDPN should not be the initial treatment choice. Rather, 
encouraging increased oral nutrition or supplements like protein drinks or bars though 
dietary counseling and education is an important first step. Every effort should also be 
made to ease dietary restrictions and financial constraints that may work to limit food 
intake. Pharmacologic agents like megestrol and gherlin may stimulate appetite, increase albumin and weight however these drugs have not been studied systematically and large-scale prospective studies are need in hemodialysis patients.18,19 Moreover, the physician should also search for identifiable causes for PEM. 
A complete gastrointestinal workup is needed to make sure there are no physical or 
structural impediments (e.g. poor dentation, dysphagia, gastroparesis) to oral intake.  
Other causes of anorexia such as depression, dementia, or inadequate dialysis should also 
be excluded. 
 
If despite the efforts described above a patient is unable to meet his nutritional intake 
goals then the option of IDPN should be discussed.9 Of note, in patients who are not 
meeting daily nutrition goals even with oral nutritional supplements and IDPN, 
placement of a feeding tube for enteral nutrition or daily total parenteral nutrition may be 
the appropriate next step. Another subgroup of hemodialysis patients in whom enteral 
nutrition or total parenteral nutrition may be beneficial are critically ill individuals. These 
persons should be treated as intensive care patients.9 
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Several nephrology and nutrition societies have commented on the management of PEM, 
including the use of intensive nutritional counseling, dietary oral supplements, and IDPN 
as shown in Table 2 and the Figure. NKF KDOQI guidelines recommend using IDPN in 
malnourished dialysis patients who are not able to increase oral ingestion with dietary 
counseling, do not tolerate oral supplementation or enteral tube feeding, and have a 
sufficient spontaneous intake that combined with the nutrients provided by IDPN can 
reach the nutritional targets.11 ESPEN guidelines suggest using IDPN in malnourished 
dialysis patients who failed nutrition counseling and oral nutrition supplements.9 
Interestingly, NKF KDOQI recommends IDPN only after enteral nutrition fails while 
ESPEN recommends IDPN as first line therapy as placement of a feeding tube is deemed 
to be higher risk than IDPN. In contrast, ASPEN does not recommend IDPN due to lack 
of adequate supporting data.10  These conflicting recommendations highlight the need for 
clinical judgment in determining which patients may benefit from IDPN.  
 
When should IDPN be discontinued once initiated? Stopping is reasonable if there is 
sustained improvement in nutritional parameters, if adverse effects of IDPN are observed 
(see next section), or if there is spontaneous improvement of caloric/protein intake thus 
making IDPN unnecessary. On the other hand, lack of improvement after 3 to 6 months 
of IDPN should also lead to discontinuation of the IDPN.5 Ultimately the decision to 
discontinue IDPN, like the decision to initiate it, is based primarily on clinical judgment. 
 
RISKS AND ADVANTAGES OF IDPN 
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There are several benefits and drawbacks of IDPN, all of which are listed in Table 3. Of 
particular interest in the known drawbacks are associated metabolic and electrolyte 
derangements. For example, IDPN is contraindicated if triglyceride levels are greater 
than 300 mg/dl because lipids present in the IDPN could exacerbate 
hypertriglyceridemia. Hyperglycemia has also been identified as a possible complication 
of IDPN. Because of the risk of electrolyte disturbances, stringent monitoring of the 
electrolytes, especially during the first weeks of IDPN support is highly recommended.9 
Depending on the compounding of the nutrient solution blood glucose, triglycerides and 
liver function tests need to be monitored on a routine basis.20 Overall IDPN has been 
demonstrated in hemodialysis patients to be safe with a low complication rate. In the 
largest randomized study of IDPN ever performed the most common adverse effects 
identified were digestive symptoms, hypotension and muscle cramps that occurred during 
treatment, but they occurred at a similar rate as in the control group (which was 
consuming oral supplementation).16 
 
CONCLUSION 
ESRD patients are at risk for PEM which is linked to a greater likelihood of adverse 
clinical outcomes.4 IDPN is a relatively safe and efficacious option for delivering 
nutrients to hemodialysis patients with reduced spontaneous oral intake. However, it is 
not designed to be the only or even the major source of nutritional sustenance. It is also 
not indicated for severely malnourished or critically ill hemodialysis patients. There are 
no studies demonstrating that IDPN improves major clinical outcomes though few 
randomized trials in this field exist.21 Therefore additional studies are needed to establish 
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the benefits of IDPN. In the meantime, clinical judgment and acumen remains key to 
diagnosing PEM and determining the need for IDPN. 
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Table 1: National Kidney Foundation Recommended Measures for Monitoring 
Nutritional status in Maintenance Dialysis Patients8  
Parameters Frequency of 
Measurements 
Comments Limitations 
Pre-dialysis serum 
albumin 
Monthly Target level is 
normal > 4g/dL 
Affected by non-
nutritional factors 
like inflammation, 
dehydration, 
infection, acid-base 
status 
% change in post 
dialysis body weight 
Monthly Trends from edema 
free body weight 
needs to be 
monitored 
Getting a true dry 
weight may be 
challenging 
Subjective global 
assessment 
Every 6 months A simple technique 
based on subjective 
and objective 
aspects of the 
medical history and 
physical 
examination 
Does not include 
visceral protein 
levels in the 
assessment. It is 
subjective and has 
not been studied 
well in hemodialysis 
population 
Dietary interview 
and/or dairy 
Every 6 months 3-day dietary 
records followed by 
interviews and 
calculating nutrient 
intake by an 
experienced 
registered renal 
dietitian 
Time consuming 
and limited by 
accuracy of 
documentation by 
patient and/or 
interview and 
calculation by 
dietician 
Normalized protein 
nitrogen appearance 
(nPNA)  
Monthly In the clinically 
stable patient, nPNA 
can be used to 
estimate protein 
intake. 
nPNA is not valid in 
catabolic or 
anabolic state. 
nPNA may fluctuate 
from day to day as a 
function of protein 
intake, and a single 
nPNA measurement 
may not reflect 
usual protein 
intakes. 
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Table 2: Society Recommendations on Indications for IDPN  
KDOQI, 200011 1. Evidence of protein or energy malnutrition and inadequate dietary 
protein and/or energy intake 
2. Inability to administer or tolerate adequate oral nutrition, including 
food supplements or tube feeding 
3. Oral or enteral intake which, when combined with IDPN, meets the 
recommended dietary intake  
ESPEN, 20099 1. IDPN improves nutritional status in undernourished hemodialysis 
patients.  
2. In outpatients, if nutritional counseling and oral nutritional 
supplements are unsuccessful, IDPN should be proposed 
ASPEN, 201010 IDPN should not be used as a nutritional supplement in malnourished 
chronic kidney disease stage 5 hemodialysis patients. 
KDOQI, Kidney Disease Outcomes Quality Initiative; ESPEN, European Society of 
Parenteral and Enteral Nutrition; ASPEN, American Society of Parenteral and Enteral 
Nutrition   
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Table 3: Advantages and Disadvantages of IDPN 
Advantages 1. No need for a dedicated enteral feeding tube or total parenteral 
nutrition vascular access 
2. Ultrafiltration during dialysis will help minimize the risks of fluid 
overload 
3. No demands on patient time or effort 
Disadvantages 1. Provides insufficient calories and protein to support long term 
daily needs 
2. Does not address the problem of improving patient’s eating 
behavior  
3. Side effects like metabolic and electrolyte abnormalities  
4. Medicare reimbursement for IDPN is complex and extremely time 
consuming  
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Figure: Flowchart for nutritional intervention in hemodialysis patients with protein 
energy malnutrition  
 
 
 
